| Dr Joseph E Sudolcan, MD | |
|
800 N Main Ave Ste 3, Big Lake, TX 76932-3900 | |
| (325) 884-3743 | |
| Not Available |
| Full Name | Dr Joseph E Sudolcan |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 39 Years |
| Location | 800 N Main Ave Ste 3, Big Lake, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811954332 | NPI | - | NPPES |
| 83X714 | Other | TX | BLUE CROSS/BLUE SHIELD TX |
| 138407509 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | H0859 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Of San Angelo Inc | San angelo, TX | Hospice |
| Reagan Memorial Hospital | Big lake, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Reagan Hospital District | 3678606399 | 4 |
News Archive
In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg~Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood-brain barrier.
Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study.
GenomOncology today announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations.
Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.
› Verified 8 days ago
| Entity Name | Reagan Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487786232 PECOS PAC ID: 3678606399 Enrollment ID: O20160831000729 |
News Archive
In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg~Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood-brain barrier.
Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study.
GenomOncology today announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations.
Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph E Sudolcan, MD 3555 Knickerbocker Rd, San Angelo, TX 76904-7610 Ph: (325) 949-9555 | Dr Joseph E Sudolcan, MD 800 N Main Ave Ste 3, Big Lake, TX 76932-3900 Ph: (325) 884-3743 |
News Archive
In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg~Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood-brain barrier.
Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study.
GenomOncology today announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations.
Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.
› Verified 8 days ago
Dr. James S. Williams, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 N Main Ave, Big Lake, TX 76932 Phone: 325-481-2183 |